H.C. Wainwright

H.C. Wainwright initiated coverage on Stemline Therapeutics Inc (NASDAQ: STML) with a Buy rating. The target price for Stemline Therapeutics is set to $38. Stemline Therapeutics shares have gained 16.51 percent over the past 52 weeks, while the S&P 500 index has surged 13.28 percent in the same...

Analysts at H.C. Wainwright initiated coverage on DARA Biosciences Inc (NASDAQ: DARA) with a Buy rating. The target price for DARA Biosciences is set to $2. DARA Biosciences shares have dropped 59.04 percent over the past 52 weeks, while the S&P 500 index has surged 13.39 percent in the same...

OvaScience Inc (NASDAQ: OVAS) extended its losses Monday on worries over testing results of its fertility treatment. Shares fell 5.3 percent recently to $41.16. The shares are off more than 12 percent in the past five trading days. OvaScience last week posted results of a small study revealing nine...

In a recent report, analysts at H.C. Wainwright outlined their 2015 outlook for healthcare stocks. Here's a breakdown of their top stocks to own in 2015. Advaxis, Inc. (NASDAQ: ADXS): Analysts are hopeful that ADXS-CHER2 will gain approval by the U.S. Department of Agriculture for...

In a report published Tuesday, H.C. Wainwright analyst Jeffrey Wright downgraded the rating on Uranerz Energy Corp. (NYSE: URZ) from Buy to Neutral, but reiterated the $2.00 price target. In the report, H.C. Wainwright noted, “On January 5, 2014 Uranerz Energy announced the execution of a...

In a report published Friday, H.C. Wainwright analyst Amit Dayal reiterated a Buy rating on RADCOM Ltd. (NASDAQ: RDCM), and raised the price target from $7.50 to $13.50. In the report, H.C. Wainwright noted, “We are increasing our price target on RDCM to $13.50 from $7.50 previously. This upward...

TG Therapeutics Inc's (NASDAQ: TGTX) increasingly attractive drug development pipeline could make it an acquisition target, an analyst said Monday. Pharmacyclics, Inc. (NASDAQ: PCYC) "represents the ideal suitor" for TG Therapeutics, according to H.C. Wainwright's Reni...

In a report published Monday, H.C. Wainwright analyst Reni Benjamin initiated coverage on TG Therapeutics (NASDAQ: TGTX) with a Buy rating and $17.00 price target. In the report, H.C. Wainwright noted, “We are initiating coverage of TG Therapeutics with a Buy rating and a target price of $17, based...

In a report published Wednesday, H.C. Wainwright analyst Andrew S. Fein reiterated a Neutral rating and $85.00 price target on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). In the report, H.C. Wainwright noted, “During the last year, we had alerted investors on the pending multiplication of...